{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.6608","value":"11.379"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.4529","value":"13.490"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"description":"Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations. It will be obtained from the Cmax parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Cmax will be missing for that subject. Cmax will be reported in units of ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"The analysis was performed in PK population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Maximum Plasma Concentration (Cmax) of Panobinostat","type":"SECONDARY","unitOfMeasure":"ng/mL"}